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A BST R AC T  
 
Aim: We aimed to compare platelet counts (Plt), plateletcrit (PCT) and platelet distribution width 
(PDW) values of type 1 diabetes mellitus (T1DM) patients with those of healthy subjects. 
Methods: The records of 39 T1DM patients who were hospitalized between January 2016 and May 
2018 were retrospectively analyzed. Control group consisted age and body mass index matched 
nondiabetic patients. Subjects having history of cardiovascular disease or any other systemic disease 
were excluded. 
Results: Compared to control group Plt (270±63 vs. 215±35 k/mm3), PCT (0.217±0.057 vs. 
0.168±0.034 %) and PDW [17.4(16.2-20.4) vs. 17(12.5-19.4) %] were significantly higher in T1DM 
patients. 
Conclusion: Platelet indices which are common, simple and inexpensive hemogram parameters are 
increased T1DM patients. 
Keywords: Type 1 diabetes mellitus, plateletcrit, inflammation, platelet counts, hematological 
indices. 
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Introduction 
Diabetes is increasing in frequency day by day. 
Due to its complications it’s a major health 
concern [1]. It’s especially associated with 
increased risk of vascular disease. 
Inflammation has been claimed for long-term 
complications of diabetes [2-5]. Inflammation 
accelerates the development of atherosclerosis 
and may trigger atherosclerotic plaque rupture 
[6]. Platelets play an important role in 
inflammation, thrombosis and atherogenesis 
and may contribute to the development of 
vascular complications in subjects with 
diabetes [7]. Contrast to type 2 diabetes Type 
1 diabetes mellitus (T1DM) develops at 
younger ages and T1DM is the most common 
form of diabetes in adolescents [8]. Therefore 
it may be important to predict possible long 
term complications by simple tests. Hemogram 
parameters have been suggested as novel 
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inflammatory markers [9-11]. Recent studies 
proposed that abnormalities in platelets indices 
could be associated with an increased risk for 
developing vascular complications in Type 2 
diabetes [12]. Platelet indices such as 
plateletcrit (PCT), platelet distribution width 
(PDW), and platelet count (Plt) have been 
investigated in the diagnosis, treatment and 
follow-up of various diseases [3, 13]. 
In the present study, we aimed to compare Plt, 
PCT and PDW values of Type 1 diabetes 
mellitus (T1DM) patients with those of healthy 
subjects. 
 
Methods  
 
Hospital records of 39 patients with T1DM 
who were followed in the endocrinology and 
metabolism diseases outpatient clinic of our 
hospital between 2016 January and May 2018 
were retrospectively analyzed. Control group 
consisted age and body mass index matched 
nondiabetic patients. The study protocol was 
approved by Bolu Abant Izzet Baysal 
University Clinical Research Ethics 
Committee, Date: 20.12.2018. Decision 
number: 2018/260. All procedures performed 
in studies involving human participants were 
in accordance with the ethical standards of the 
institutional and/or national research 
committee and with the 1964 Helsinki 
declaration and its later amendments or 
comparable ethical standards.  
T1DM was defined according to the American 
Diabetes Association criteria [14]. Age, 
gender, body mass index, hypertension and 
echocardiographic parameters such as ejection 
fraction (EF), left ventricular diastolic 
diameters (LVDD) and laboratory parameters, 
such as fasting plasma glucose, creatinine, 
white blood cell count (WBC), hemoglobin 
(Hb), hematocrit (Htc), mean corpuscular 
volume (MCV), red cell distribution width 
(RDW), Plt, mean platelet volume (MPV), 
were obtained from database and patient files 
of the institution. 
Subjects having history of coronary artery 
disease, peripheral artery disease, heart failure, 
structural heart disease, chronic lung disease, 
liver or renal failure, thyroid disorders, 
malignancies, electrolyte imbalances or any 
other systemic disease were excluded. 
Peripheral venous blood samples were drawn 
from patients who during regular follow-up 
checkups. Serum glucose, creatinine, total 
cholesterol, high-density lipoprotein 
cholesterol, triglyceride and low-density 
lipoprotein cholesterol were measured using an 
automatic biochemical analyzer (Architect 
C8000, USA). Complete blood count and 
platelet volumes were determined using 
simultaneous optical and impedance 
measurements (Cell Dyn 3700; Abbott 
Diagnostics, Lake Forest, Illinois, USA). 
Platelet, neutrophil, lymphocyte, monocytes, 
eosinophil, white blood cell (WBC), platelet 
distribution width (PDW), red cell distribution 
width (RDW), mean platelet volume (MPV) 
and PCT values of each patient were recorded.  
 
Statistical analysis 
Statistical analysis was conducted with SPSS 
software (SPSS 18.0 for Windows, IBM Co, 
Chicago, IL, USA). Distribution of the 
variables in study groups were analyzed by 
Kolmogorov-Smirnov test. Normal distributed 
variables were compared by T test and 
expressed as mean±standard deviation. 
Variables without normal distribution were 
compared with Mann Whitney U test and 
expressed as median (IQR: interquartilerange). 
Chi-square test was used for comparison of 
nonparametric variables. A p value lower than 
0.05 was considered statistically significant. 
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Results 
Mean age, body mass index (BMI) and 
frequencies of sex, hypertension, smoking and 
hyperlipidemia were not significantly different 
between study patients and control group 
(Table 1). Compared to control group fasting 
plasma glucose (276 (116-535) vs. 96 (78-111) 
mg/dL, p<0.001), triglyceride (104 (47-395) 
vs. 81 (33-208) mg/dL, p=0.040); total 
cholesterol 186 (108-305) vs. 160 (124-220) 
mg/dL, p=0.007); PDW [17.4 (16.2-20.4) vs. 
17 (12.5-19.4) %, p=0.043); neutrophil count 
(4.72 (2.28-6.75) vs. 3.65 (2.29-5.55) u/mm3, 
p=0.022);  LVDD 4.5 (3.3-5.2) vs. 4.5 (4.2-
5.1) cm, p=0.033); Plt (270±63 vs. 215±35 
k/mm3, p<0.001); WBC (7.7±1.5 vs. 6.4±1.2 
u/mm3, p=0.001); lymphocyte count 
(2.40±0.50 vs. 2.01±0.47 u/mm3, p= 0.001) 
and PCT (0.217±0.057 vs. 0.168±0.034 %, 
p<0.001) were significantly higher in T1DM 
patients. There were no significant differences 
in creatinine, LDL-cholesterol and HDL-
cholesterol levels, hemoglobin, MPV, 
eosinophil and monocyte counts, RDW and 
LVEF between two groups (Table 2). 
 
Table 1. General characteristics of the study 
groups. 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
T1DM is an autoimmune disease process that 
develops through the interaction of genetic and 
environmental factors. It is characterized by 
progressive beta-cell destruction as a result of 
inflammation in the pancreas and total insulin 
deficiency as a result [15]. DM is a 
‘prothrombotic state’ associated with 
atherosclerosis and inflammation. Tendency to 
thrombosis is increased in DM patients with 
increased platelet reactivity [16]. 
Hyperglycemia contributes to heightened 
platelet reactivity through glycation of platelet 
proteins. Besides, hypertriglyceridemia also 
increases platelet reactivity [17]. Insulin has 
also been shown to antagonize the effect of 
platelet agonists [18].  
Chronic complications such as nephropathy, 
retinopathy, neuropathy microangiopathy and 
macroangiopathy are the most important 
problems of T1DM patients. The 
microvascular complications of diabetes are 
major causes of morbidity in diabetics and are 
generally detected quite late [3]. Early 
diagnosis of late complications of T1DM is 
very important in terms of prolongation and 
improvement of life [19-21]. Several studies 
have shown that platelet aggregation plays a 
role in the development of microvascular and 
macrovascular disease in DM patients [16].  
Platelet activation plays central role in the 
pathogenesis of homeostasis and thrombosis 
[22]. Furthermore, platelets play important role 
in inflammatory process. Endothelial 
dysfunction and inflammation has been 
claimed for long-term complications of 
diabetes [2-5]. Inflammation accelerates the 
development of atherosclerosis. Platelets may 
play a role through both thrombogenic 
mechanisms, inflammatory pathways.  
Plt has been found to be increased in 
cardiovascular diseases and vascular 
complications [23-25]. PDW and PCT are 
platelet parameters reflecting thrombotic 
activity [26].   PCT   is  a  parameter of platelet  
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concentration and provides information on 
platelet production and activity [27]. It has 
been shown that there is a relationship between 
Plt and PCT reflecting the risk of platelet 
activation and potential thrombotic event [28].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent studies have suggested that PCT can 
provide more comprehensive and correct 
information about platelet activation [17, 29]. 
Some studies have shown that PCT has the 
potential to predict the risk of thrombosis. In 
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some studies, PCT was found to be associated 
with coronary artery disease [23-25]. 
We thought that PCT values may give us more 
accurate results about the course of diabetic 
cardiovascular complications. PCT may be 
associated with thrombotic activity that 
predicts cardiovascular mortality and 
morbidity in T1DM. 
 
Conclusion 
Our findings suggest that Plt and PCT are 
increased in T1DM. When these results are 
verified by larger-scale studies, this may lead 
to modification of the treatment strategies 
based on follow-up these indices. 
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